Exavir Aims CRISPR Program at HIV, Sees Powerful Preclinical Results

Since HIV first reared its deadly head 40 years ago, multiple medications have been developed, and drug makers continue to search for the Holy Grail in HIV treatment and create a potential cure for the disease. Exavir Therapeutics believes it has a chance to hit that mark with its gene editing program.